However, despite clear beneficial effects in mice that are genetically modified to overexpress Tau [36, 138], anti-Tau monoclonals tested thus far in MCI and early sAD patients failed to demonstrate efficacy or even worsened cognitive decline [54, 86, 119]. The gene discussed is MAPT; the disease is Mental deterioration.